JDRF Blog

Latest in Immunotherapies

  • FDA Breakthrough Therapy Designation for Teplizumab—Based on the First Study to Delay the Onset of T1D for 2+ Years

    August 5, 2019

    The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to teplizumab, an anti-CD3 monoclonal antibody, for the prevention or delay...

  • ADA Scientific Sessions Recap—Day #4: Simi Ahmed, Ph.D.

    June 11, 2019

    The American Diabetes Association’s Scientific Sessions is almost coming to a close! Here is Simi Ahmed, Ph.D., head of the immunotherapy program...

  • First Human Study to Significantly Delay—by Two Years!—Type 1 Diabetes Onset

    June 9, 2019

    This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immunotherapy demonstrated a...

  • Your Cancer is Gone; Type 1 Diabetes is Here

    May 31, 2019

    Immunotherapy has transformed cancer care. In some cases, cancer is effectively cured in people with stage 4 disease. But it has a...

  • Closer to Cure: Renewed Funding for Type 1 Diabetes UK Immunotherapy Consortium (T1D UK)

    May 8, 2019

    More than 400,000 people in the United Kingdom and 1.25 million Americans have type 1 diabetes (T1D), a disease for which there...

  • JDRF-Backed Start-Up Company to Accelerate Work Through Pfizer

    March 5, 2019

    AnTolRx, Inc., a private biotechnology company, has agreed to license its immune tolerance therapy for type 1 diabetes (T1D) to Pfizer with...

  • JDRF Drives Next-Generation Type 1 Diabetes Research With New Partnerships & Breakthrough Science

    December 22, 2018

    JDRF, the leading global organization funding type 1 diabetes (T1D) research, announced today that it made progressive advances this year on its...

  • Immunology of Diabetes Society Congress Brings World-Renowned Minds to London, England

    October 24, 2018

    Every 18 months, researchers from around the world gather for the Immunology of Diabetes Society (IDS) Congress, which is taking place this...

  • Can a T1D Scientist Learn from a Cancer Researcher? You Bet

    July 20, 2018

    The type 1 diabetes (T1D) research community has continued to reflect on the overlapping biology of cancer immunity and other autoimmune disorders....